Vivos Therapeutics Inc
NASDAQ:VVOS
Vivos Therapeutics Inc
Cost of Revenue
Vivos Therapeutics Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
Cost of Revenue
-$5.5m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
DaVita Inc
NYSE:DVA
|
Cost of Revenue
-$8.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cost of Revenue
-$6.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
CVS Health Corp
NYSE:CVS
|
Cost of Revenue
-$307.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-11%
|
|
Cigna Corp
NYSE:CI
|
Cost of Revenue
-$180.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cost of Revenue
-$8.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-9%
|
See Also
What is Vivos Therapeutics Inc's Cost of Revenue?
Cost of Revenue
-5.5m
USD
Based on the financial report for Dec 31, 2023, Vivos Therapeutics Inc's Cost of Revenue amounts to -5.5m USD.
What is Vivos Therapeutics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-39%
Over the last year, the Cost of Revenue growth was 8%. The average annual Cost of Revenue growth rates for Vivos Therapeutics Inc have been -28% over the past three years , -39% over the past five years .